Moderna, COVID
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
Moderna posted a narrower-than-expected loss for the first quarter as the company's cost-cutting efforts took hold and sales of its Covid vaccine topped estimates. The results come as Moderna inches closer to having another product on the market,
Moderna said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC) advisers to recommend the company's ...
Moderna invested part of its vaccine windfall into a new gene-editing startup, Metagenomi. Now it's backing out.
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Moderna shares shot up about 7% Thursday after reporting better-than-expected quarterly sales and signaling confidence in a ...
With Moderna’s COVID-19 sales on the backfoot following the switch to an endemic vaccine market, the Massachusetts-based ...
Much of Moderna’s focus is on nabbing FDA approval for a respiratory syncytial virus vaccine, a decision expected in a matter ...
Analyst Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report) and increased the price target to $75.00 from $0.00. Tyler Van Buren’s rating is based on a careful ...
The PFS ready-to-use formulation will save pharmacists and clinicians time, potentially alleviating wait times and reducing ...
Earlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting stage left on a partnership ...
Moderna Inc.’s stock jumped 9% Thursday as the company reported a narrower-than-expected first-quarter loss and looks toward ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results